Thor Halfdanarson, Medical Oncologist at the Mayo Clinic, shared a post on X:
“PRRT is a very effective for well-differentiated NETs but associated with a low risk of treatment related myeloid neoplasms ( t-MN ). If you are interested in learning more, this is the review for you.”